, Columnist
Patents, Trump, Viagra: My Good and Bad Calls of 2017
One more look back at some things I wrote about last year.
Happy generic New Year.
Photographer: David Williams/BloombergWith 2017 barely in the rearview mirror, I thought I would take a minute to look back at some of the things I wrote about during my first year as a Bloomberg View columnist. Like most people in the opinion racket, I got some right and got some wrong. In either case, the more interesting question is why. Here goes:
In June, I wrote about a securities class-action lawsuit that had been filed against Bill Ackman, who runs Pershing Square Capital Management, as well as Valeant Pharmaceuticals International Inc. I thought that the suit posed a serious threat to the hedge fund activist and the company.